| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |